Mike Slive Foundation Awards Six Prostate Cancer Research Grants

BIRMINGHAM, ALABAMA –The Mike Slive Foundation has named its newest research grant recipients, continuing the Foundation’s mission to eradicate prostate cancer through research funding and education. Since its inception in 2017, the Mike Slive Foundation is proud to have funded 39 innovative prostate cancer research grants.

The Mike Slive Foundation’s mission is to fund cutting-edge prostate cancer research pilot grants that enables a scientist to create proof of concept and hopefully go on to receive larger federal grants. “My father was the recipient of a clinical trial during his prostate cancer treatment,” said Anna Slive Harwood, Executive Director of the Mike Slive Foundation. “The research we fund aims to address all aspects of prostate cancer detection and treatment, ranging from initial diagnosis to improving quality of life for patients and survivors. We’re so proud to invest funds in these grants that we hope will get us closer to eradicating prostate cancer in our lifetime.”

The Mike Slive Foundation 2024-25 Research Grant Recipients include:

• PSMA targeted sialidase for prostate cancer immunotherapy, Dr. James D. Brooks, Stanford University.
• Harnessing TMPRSS2-ERG Fusion-Derived Neoantigens for an Off-the-Shelf Prostate Cancer Vaccine, Dr. Nina Bhardwaj and Dr. Mesude Bicak, Icahn School of Medicine at Mount Sinai.
• Targeting dopa decarboxylase (DDC)-dependent metabolic reprogramming to overcome immunotherapy resistance in NEPC, Dr. Guocan Wang, The University of Texas MD Anderson Cancer Center.
• Investigating PTGES3 as a Novel Therapeutic Target in Advanced Prostate Cancer, Dr. Haolong Li, Fred Hutchinson Cancer Center.
• Murine Modeling and Immunotherapeutic Targeting of GPC3 Positive Prostate Cancer, Dr. Christopher J. Pirozzi and Dr. Jiaoti Huang, Duke University Medical Center.
• Developing CAR-NKT cells to reprogram the Tumor Microenvironment in Prostate Cancer, Tonya J. Webb, University of Maryland, Baltimore.